Veeva Systems (NYSE:VEEV) & 10x Genomics (NASDAQ:TXG) Head to Head Analysis

Veeva Systems (NYSE:VEEV) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and price targets for Veeva Systems and 10x Genomics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veeva Systems	1	8	18	0	2.63
10x Genomics	1	10	4	0	2.20

Veeva Systems presently has a consensus target price of $250.96, suggesting a potential upside of 45.10%. 10x Genomics has a consensus target price of $23.17, suggesting a potential downside of 25.37%. Given Veeva Systems’ stronger consensus rating and higher possible upside, equities analysts plainly believe Veeva Systems is more favorable than 10x Genomics.

Institutional & Insider Ownership

88.2% of Veeva Systems shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 10.6% of Veeva Systems shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Veeva Systems and 10x Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veeva Systems	28.37%	13.89%	11.57%
10x Genomics	-3.55%	-2.86%	-2.23%

Earnings & Valuation

This table compares Veeva Systems and 10x Genomics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veeva Systems	$3.20 billion	8.84	$908.91 million	$5.61	30.83
10x Genomics	$642.82 million	6.13	-$43.54 million	($0.17)	-182.59

Veeva Systems has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Veeva Systems has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.

Summary

Veeva Systems beats 10x Genomics on 13 of the 14 factors compared between the two stocks.

About Veeva Systems

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.